Physician profile
Alexander Tal
NPI 1306879374
$8,704.67
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,654 · 2020: $248 · 2021: $1,779 · 2022: $23.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $3,085.45 | 2019-2020 | |
| Novo Nordisk INC | $2,460.61 | 2019-2021 | |
| Lilly USA, LLC | $566.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $498.16 | 2019-2020 | |
| Becton, Dickinson and Company | $345.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $312.69 | 2019-2021 | |
| Abbvie INC. | $223.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $205.19 | 2019-2020 | |
| Amgen INC. | $174.70 | 2019 | |
| Shire North American Group INC | $156.52 | 2019 | |
| Insulet Corporation | $132.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.51 | 2019 | |
| Abbott Laboratories | $79.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $54.75 | 2019-2020 | |
| Vivus LLC | $43.24 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $42.35 | 2019 | |
| Amarin Pharma, INC. | $42.16 | 2019-2020 | |
| Antares Pharma, INC. | $35.42 | 2019 | |
| Lifescan, INC. | $30.70 | 2019 | |
| Currax Pharmaceuticals LLC | $28.35 | 2019-2020 | |
| Ibsa Pharma INC. | $27.56 | 2019 | |
| Pfizer INC. | $23.04 | 2022 | |
| Medtronic Minimed, INC. | $15.66 | 2019 | |
| Strongbridge US INC. | $14.36 | 2019 | |
| Radius Health, INC. | $12.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Tal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.